BioSpace News Archive

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.

Ocugen, Inc. today announced that it will host a conference call and simultaneuous webcast to discuss the Company’s second quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Friday, August 5, 2022.

As temperatures rise across the country, Cigna will provide its Medicare Advantage customers rides to community cooling centers to safely find relief from the heat.

AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3 on the agenda at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on August 12, 2022.

Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock.

ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced it will host a first of its kind symposium focused on the shift toward emerging therapies for people diagnosed with OSA.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has completed dosing the first participant in the phase I clinical study in China for its self-developed, innovative drug LNK01004.